1
|
Guan J, Shen L, Liu C, Lv Y, Zhang H, Liu Y, Gai Z. Establishment of iPS cell line (SDQLCHi061-A) from a patient with carbamoylphosphate synthetase I deficiency due to CPS1 mutation. Stem Cell Res 2024; 76:103353. [PMID: 38394969 DOI: 10.1016/j.scr.2024.103353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 02/06/2024] [Accepted: 02/16/2024] [Indexed: 02/25/2024] Open
Abstract
The induced pluripotent stem cells (iPSCs) line was generated using peripheral blood mononuclear cells (PBMCs) from a patient with compound heterozygous mutation of c.2374A > G/p.M792V and c.3949C > T/p.R1317W in the CPS1 gene by non-integrating vectors. The expression of pluripotency markers, potential for in vitro trilineage differentiation and exhibiting normal karyotype were demonstrated in the SDQLCHi061-A cell line. This cell line could provide a useful CPS1D model in vitro for further study.
Collapse
Affiliation(s)
- Jingyun Guan
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China
| | - Li Shen
- Clinical Lab, The Forth Hospital of Jinan, Jinan 250031, China
| | - Chen Liu
- Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China; Department of Neonatology, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China
| | - Yuqiang Lv
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China
| | - Haiyan Zhang
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China
| | - Yi Liu
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China
| | - Zhongtao Gai
- Pediatric Research Institute, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan 250022, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan 250022, China
| |
Collapse
|
2
|
Mahé M, Rios-Fuller TJ, Karolin A, Schneider RJ. Genetics of enzymatic dysfunctions in metabolic disorders and cancer. Front Oncol 2023; 13:1230934. [PMID: 37601653 PMCID: PMC10433910 DOI: 10.3389/fonc.2023.1230934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 07/19/2023] [Indexed: 08/22/2023] Open
Abstract
Inherited metabolic disorders arise from mutations in genes involved in the biogenesis, assembly, or activity of metabolic enzymes, leading to enzymatic deficiency and severe metabolic impairments. Metabolic enzymes are essential for the normal functioning of cells and are involved in the production of amino acids, fatty acids and nucleotides, which are essential for cell growth, division and survival. When the activity of metabolic enzymes is disrupted due to mutations or changes in expression levels, it can result in various metabolic disorders that have also been linked to cancer development. However, there remains much to learn regarding the relationship between the dysregulation of metabolic enzymes and metabolic adaptations in cancer cells. In this review, we explore how dysregulated metabolism due to the alteration or change of metabolic enzymes in cancer cells plays a crucial role in tumor development, progression, metastasis and drug resistance. In addition, these changes in metabolism provide cancer cells with a number of advantages, including increased proliferation, resistance to apoptosis and the ability to evade the immune system. The tumor microenvironment, genetic context, and different signaling pathways further influence this interplay between cancer and metabolism. This review aims to explore how the dysregulation of metabolic enzymes in specific pathways, including the urea cycle, glycogen storage, lysosome storage, fatty acid oxidation, and mitochondrial respiration, contributes to the development of metabolic disorders and cancer. Additionally, the review seeks to shed light on why these enzymes represent crucial potential therapeutic targets and biomarkers in various cancer types.
Collapse
Affiliation(s)
| | | | | | - Robert J. Schneider
- Department of Microbiology, Grossman NYU School of Medicine, New York, NY, United States
| |
Collapse
|
3
|
Wang S, Chen J, Zhu X, Huang T, Xu H, Ying G, Qian H, Lin W, Tung Y, Khan KU, Guo H, Zheng G, Lu H, Zhang G. Clinical and genetic analysis of a case of late onset carbamoyl phosphate synthase I deficiency caused by CPS1 mutation and literature review. BMC Med Genomics 2023; 16:145. [PMID: 37365635 DOI: 10.1186/s12920-023-01569-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 06/02/2023] [Indexed: 06/28/2023] Open
Abstract
BACKGROUND Carbamoyl phosphate synthetase I defect (CPS1D) is a rare disease with clinical case reports mainly in early neonates or adults, with few reports of first onset in late neonatal to childhood. We studied the clinical and genotypic characteristics of children with childhood onset CPS1D caused by two loci mutations (one of these is a rarely reported non-frame shift mutation) in the CPS1. CASE PRESENTATION We present a rare case of adolescent-onset CPS1D that had been misdiagnosed due to atypical clinical features, and further investigations revealed severe hyperammonemia (287µmol/L; reference range 11.2 ~ 48.2umol/L). MRI of the brain showed diffuse white matter lesions. Blood genetic metabolic screening showed elevated blood alanine (757.06umol/L; reference range 148.8 ~ 739.74umol/L) and decreased blood citrulline (4.26umol/L; reference range 5.45 ~ 36.77umol/L). Urine metabolic screening showed normal whey acids and uracil. Whole-exome sequencing revealed compound heterozygous mutations in the CPS1, a missense mutation (c.1145 C > T) and an unreported de novo non-frame shift mutation (c.4080_c.4091delAGGCATCCTGAT), respectively, which provided a clinical diagnosis. CONCLUSION A comprehensive description of the clinical and genetic features of this patient, who has a rare age of onset and a relatively atypical clinical presentation, will facilitate the early diagnosis and management of this type of late onset CPS1D and reduce misdiagnosis, thus helping to reduce mortality and improve prognosis. It also provides a preliminary understanding of the relationship between genotype and phenotype, based on a summary of previous studies, which reminds us that it may help to explore the pathogenesis of the disease and contribute to genetic counselling and prenatal diagnosis.
Collapse
Affiliation(s)
- Shangyu Wang
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | | | - Xiaoqi Zhu
- Nanjing Medical University, Nanjing, China
| | - Tingting Huang
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Haifeng Xu
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Guohuan Ying
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Hao Qian
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Wenxin Lin
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Yiehen Tung
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Kaleem Ullah Khan
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Hu Guo
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Guo Zheng
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Haiying Lu
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China
| | - Gang Zhang
- Department of Neurology, Children's Hospital of Nanjing Medical University, No.72 Guangzhou Road, Nanjing, Jiangsu, China.
| |
Collapse
|
4
|
Bai R, He AL, Guo J, Li Z, Yu X, Zeng J, Mi Y, Wang L, Zhang J, Yang D. Novel pathogenic variant (c.2947C > T) of the carbamoyl phosphate synthetase 1 gene in neonatal-onset deficiency. Front Neurosci 2022; 16:1025572. [PMID: 36340787 PMCID: PMC9634248 DOI: 10.3389/fnins.2022.1025572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 10/06/2022] [Indexed: 11/13/2022] Open
Abstract
Background Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is a rare autosomal recessive urea cycle disorder characterized by hyperammonaemia. The biochemical measurement of the intermediate metabolites is helpful for CPS1D diagnosis; it however cannot distinguish CPS1D from N-acetylglutamate synthetase deficiency. Therefore, next-generation sequencing (NGS) is often essential for the accurate diagnosis of CPS1D. Methods NGS was performed to identify candidate gene variants of CPS1D in a Asian neonatal patient presented with poor feeding, reduced activity, tachypnea, lethargy, and convulsions. The potential pathogenicity of the identified variants was predicted by various types of bioinformatical analyses, including evolution conservation, domain and 3D structure simulations. Results Compound heterozygosity of CPS1D were identified. One was in exon 24 with a novel heterozygous missense variant c.2947C > T (p.P983S), and another was previously reported in exon 20 with c.2548C > T (p.R850C). Both variants were predicted to be deleterious. Conservation analysis and structural modeling showed that the two substituted amino acids were highly evolutionarily conserved, resulting in potential decreases of the binding pocket stability and the partial loss of enzyme activity. Conclusion In this study, two pathogenic missense variants were identified with NGS, expanding the variants pectrum of the CPS1 gene. The variants and related structural knowledge of CPS enzyme demonstrate the applicability for the accurate diagnosis of CPS1D.
Collapse
Affiliation(s)
- Ruimiao Bai
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - ALing He
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Jinzhen Guo
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Zhankui Li
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Xiping Yu
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - JunAn Zeng
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Yang Mi
- Department of Obstetrics, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Lin Wang
- Genetics Center, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Jingjing Zhang
- Medical Imaging Center, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| | - Dong Yang
- Department of Neonatology, Northwest Women’s and Children’s Hospital, Xi’an, Shaanxi, China
| |
Collapse
|
5
|
Selvanathan A, Demetriou K, Lynch M, Lipke M, Bursle C, Elliott A, Inwood A, Foyn L, McWhinney B, Coman D, McGill J. N‐acetylglutamate synthase deficiency with associated 3‐methylglutaconic aciduria: A case report. JIMD Rep 2022; 63:420-424. [PMID: 36101823 PMCID: PMC9458610 DOI: 10.1002/jmd2.12318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 07/01/2022] [Accepted: 07/12/2022] [Indexed: 11/05/2022] Open
Affiliation(s)
- Arthavan Selvanathan
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Kalliope Demetriou
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Matthew Lynch
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Michelle Lipke
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Carolyn Bursle
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Aoife Elliott
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Anita Inwood
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
| | - Leanne Foyn
- Chemical Pathology, Central Laboratory Pathology Queensland Herston Australia
| | - Brett McWhinney
- Chemical Pathology, Central Laboratory Pathology Queensland Herston Australia
| | - David Coman
- Queensland Lifespan Metabolic Medicine Service Queensland Children's Hospital Brisbane Australia
- School of Medicine University of Queensland Brisbane Australia
| | - Jim McGill
- Chemical Pathology, Central Laboratory Pathology Queensland Herston Australia
| |
Collapse
|
6
|
Ishikawa R, Sugimoto T, Abe T, Ohno N, Tazuma T, Giga M, Naito H, Kono T, Nomura E, Hara K, Yorifuji T, Yamawaki T. A 36-year-old Man with Repeated Short-term Transient Hyperammonemia and Impaired Consciousness with a Confirmed Carbamoyl Phosphate Synthase 1 Gene Monoallelic Mutation. Intern Med 2022; 61:1387-1392. [PMID: 34670888 PMCID: PMC9152872 DOI: 10.2169/internalmedicine.7961-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
A 36-year-old man experienced severely impaired consciousness twice after drinking because of hyperammonemia. No abnormal blood tests were found other than ammonia levels. However, magnetic resonance imaging (MRI) showed atrophy of the brain parenchyma. One the second occasion, the patient suffered severe impairment of consciousness, and because of seizures and glossoptosis, mechanical ventilation was started. Urea cycle disorders (UCDs) were assumed to be involved. Genetic testing revealed a monoallelic mutation of the carbamoyl phosphate synthase 1 (CPS1) gene. When transient hyperammonemia of unknown cause occurs repeatedly in adults, an active investigation for UCDs should be conducted.
Collapse
Affiliation(s)
- Ruoyi Ishikawa
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Takamichi Sugimoto
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Takafumi Abe
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Narumi Ohno
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Taku Tazuma
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Mayumi Giga
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Hiroyuki Naito
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Tomoyuki Kono
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Eiichi Nomura
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| | - Keiichi Hara
- Department of Pediatrics and Institute for Clinical Research, NHO Kure Medical Center, Japan
| | - Tohru Yorifuji
- Division of Pediatric Endocrinology and Metabolism, Osaka City General Hospital, Japan
| | - Takemori Yamawaki
- Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Japan
| |
Collapse
|
7
|
Nitzahn M, Lipshutz GS. CPS1: Looking at an ancient enzyme in a modern light. Mol Genet Metab 2020; 131:289-298. [PMID: 33317798 PMCID: PMC7738762 DOI: 10.1016/j.ymgme.2020.10.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 10/02/2020] [Accepted: 10/03/2020] [Indexed: 02/06/2023]
Abstract
The mammalian urea cycle (UC) is responsible for siphoning catabolic waste nitrogen into urea for excretion. Disruptions of the functions of any of the enzymes or transporters lead to elevated ammonia and neurological injury. Carbamoyl phosphate synthetase 1 (CPS1) is the first and rate-limiting UC enzyme responsible for the direct incorporation of ammonia into UC intermediates. Symptoms in CPS1 deficiency are typically the most severe of all UC disorders, and current clinical management is insufficient to prevent the associated morbidities and high mortality. With recent advances in basic and translational studies of CPS1, appreciation for this enzyme's essential role in the UC has been broadened to include systemic metabolic regulation during homeostasis and disease. Here, we review recent advances in CPS1 biology and contextualize them around the role of CPS1 in health and disease.
Collapse
Affiliation(s)
- Matthew Nitzahn
- Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Gerald S Lipshutz
- Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA; Semel Institute for Neuroscience, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
| |
Collapse
|